Spain’s Idoven gathers $19.8m to fight heart problems

• Idoven is focused on advancing early detection and precision medicine of cardiovascular disease
• The round is also supplemented by a $6.9 million in grant and equity funding awarded by the European Innovation Council Accelerator
• The funding will be used to further develop the company’s AI platform to identify arrhythmias and cardiac abnormalities as well as accelerate hiring

Madrid-based health tech company Idoven has raised $19.8 million in funding, including a $12.9 million Series A round co-led by Insight Partners and Northzone with participation from Wayra. The round is also supplemented by $6.9 million in grant and equity funding awarded by the European Innovation Council Accelerator.

“Idoven has the chance to improve healthcare and save lives, at scale,” Insight Partners managing director Scott Barclay said in a statement. “This is the essence of the type of software-driven technology and empathy that Insight looks for in early healthcare investments.”

The new funding will be used to further develop the company’s best-in-class AI platform to identify arrhythmias and cardiac abnormalities, as well as accelerate hiring to build on its mission to advance early diagnosis and precision medicine of cardiovascular diseases.

The round’s angel investors include Ron Vianu, founder and CEO of Covera Health; Brad Fluegel, former chief healthcare commercial officer at Walgreens; and Vlad Lata, founder and CEO of Avi Medical. This round follows a $2 million seed round raised a year ago from business angels, Wayra and the Accel Starter program.